Avid Bioservices, Inc. (CDMO)
| Market Cap | 786.66M |
| Revenue (ttm) | 142.36M |
| Net Income (ttm) | -144.17M |
| Shares Out | 63.96M |
| EPS (ttm) | -2.28 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,171,839 |
| Open | 12.29 |
| Previous Close | 12.25 |
| Day's Range | 12.25 - 12.30 |
| 52-Week Range | 4.07 - 12.48 |
| Beta | 1.40 |
| Analysts | Buy |
| Price Target | 13.63 (+10.81%) |
| Earnings Date | Dec 5, 2024 |
About CDMO
Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line developme... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for CDMO stock is "Buy." The 12-month stock price forecast is $13.63, which is an increase of 10.81% from the latest price.
News
Punch and Associates sends letter to Board of Directors of Avid Bioservices, Inc.
MINNEAPOLIS--(BUSINESS WIRE)--Punch & Associates intends to vote AGAINST proposed acquisition of Avid Bioservices, Inc. by GHO Capital and Ampersand Capital.
AVID BIOSERVICES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avid Bioservices, Inc. - CDMO
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Avid Bioservices...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Avid Bioservices, Inc.
NEW YORK , Nov. 7, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Avid Bioservices, Inc. (NASDAQ: CDMO) and its board of directors concerning the proposed...
Avid Bioservices to be acquired by GHO and Ampersand for about $1.1 bln
Avid Bioservices said on Wednesday that it has agreed to be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners in a deal valued at about $1.1 billion.
Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Transaction
TUSTIN, Calif. and LONDON and BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing or...
Avid Bioservices to Participate in Craig-Hallum Bioprocessing Conference
TUSTIN, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient li...
Avid Bioservices, Inc. (CDMO) Q1 2025 Earnings Call Transcript
Avid Bioservices, Inc. (NASDAQ:CDMO) Q1 2025 Earnings Conference Call September 9, 2024 4:30 PM ET Company Participants Tim Brons - IR, Vida Strategic Partners Nick Green - President and CEO Dan Hart...
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024
-- Recorded First Quarter Revenue of $40.2 Million -- -- Signed $66 Million in Net New Business, Resulting in Backlog of $219 Million --
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024
TUSTIN, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient liv...
Avid Bioservices, Inc. (CDMO) Q4 2024 Earnings Call Transcript
Avid Bioservices, Inc. (NASDAQ:CDMO) Q4 2024 Earnings Conference Call July 2, 2024 4:30 PM ET Company Participants Tim Brons - IR, Vida Strategic Partners Nick Green - President & CEO Dan Hart - CFO ...
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024
-- Recorded Fourth Quarter Revenue of $43.0 Million – Highest in Company History -- -- Signed $30 Million in Net New Business Resulting in Backlog of $193 Million --
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024
TUSTIN, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient live...
Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance
TUSTIN, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient live...
Avid Bioservices: A Unique Growth Story With Many Tailwinds And Catalysts
Although Avid is 30+ years old, the story has become much more exciting due to the shift to a pure-play biologics CDMO, pharma increasingly outsourcing biologics, and record revenue-generating capacit...
Avid Bioservices to Participate at Upcoming Investor Conferences
TUSTIN, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient live...
Avid Bioservices, Inc. (CDMO) Q3 2024 Earnings Call Transcript
Avid Bioservices, Inc. (NASDAQ:CDMO) Q3 2024 Earnings Conference Call April 29, 2024 4:30 PM ET Company Participants Tim Brons – Investors Relations Group Nick Green – President and Chief Executive O...
Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024
-- Recorded Third Quarter Revenue of $33.8 Million -- -- Signed $41 Million in Net New Business Resulting in Record High Backlog of $206 Million --
Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q
TUSTIN, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (Nasdaq:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today it received a...
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Avid Bioservices, Inc. (CDMO) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Avid Bioservices,...
Avid Bioservices, Inc. (CDMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK--(BUSINESS WIRE)---- $CDMO #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Avid Bioservices, Inc. (“Avid Bi...
The Law Offices of Frank R. Cruz Announces Investigation of Avid Bioservices, Inc. (CDMO) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Avid Bioservices, Inc. (“Avid” or the “Company”) (NASDAQ: CDMO) on behalf of investors concerning the Compa...
Avid Bioservices Announces Pricing of Private Placement of Convertible Notes
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today the pricing o...
Avid Bioservices Announces Proposed Private Placement of Convertible Notes
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today that it inten...
Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient liv...
Avid Bioservices: Don't Miss The Bigger Picture
Avid Bioservices has invested heavily in building new facilities, causing lower margins and negative free cash flow. The company's recent expansion projects have increased its revenue capacity to $400...